Readouts from two phase 3 clinical trials demonstrated that Eli Lilly and Company’s Ultra Rapid Lispro (URLi) met the primary efficacy endpoint of non-inferior A1C reduction from baseline compared to Humalog (insulin lispro) and also demonstrated significantly improved post-meal glucose control in people with type 1 and type 2 diabetes.
![[branded content] De vijf belangrijkste customer experience trends voor 2024](https://www.pharmamarketeer.nl/wp-content/uploads/2024/04/customer-experience-80x60.jpg)
Reageer